Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with ...

Moderna’s share price popped in August on positive news about its therapeutic cancer vaccine to prevent melanoma from ...

Moderna Inc. MRNA shares are trading higher Friday, extending a rally that carried the stock to a fresh 52-week high near ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged annual losses over that period -- enough to turn a single $10,000 ...

Sanofi (Nasdaq: SNY) deprioritized its mRNA flu shot effort. But it is still vigorously defending its substantial share of the flu vaccine market, with its egg-grown Fluzone products and egg-free ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.

Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected ...

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be.

Moderna stock jumped 7% on Thursday, September 24, closing at $195 as investors kept betting on intismeran autogene’s Phase 3 melanoma data due at ESMO on October 24. Street Split: The 23 analysts ...

One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.